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Abstract
Extraintestinal pathogenic E. coli (ExPEC) are the major aetiological agent of urinary tract infections (UTIs) in humans. The
emergence of the CTX-M producing clone E. coli ST131 represents a major challenge to public health worldwide. A recent
study on the metabolic potential of E. coli isolates demonstrated an association between the E. coli ST131 clone and
enhanced utilisation of a panel of metabolic substrates. The studies presented here investigated the metabolic potential of
ST131 and other major ExPEC ST isolates using 120 API test reagents and found that ST131 isolates demonstrated a lower
metabolic activity for 5 of 120 biochemical tests in comparison to non-ST131 ExPEC isolates. Furthermore, comparative
phenotypic microarray analysis showed a lack of specific metabolic profile for ST131 isolates countering the suggestion that
these bacteria are metabolically fitter and therefore more successful human pathogens.
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Introduction
Urinary tract infections (UTIs) are among the most common
bacterial infections acquired both in the community and hospital
settings [1]. UTIs occur in all age groups and in both genders
[2,3], while their incidence increases with age [4]. Additionally,
they are more common in women than men [2], with an estimated
33% of women suffering from a UTI by the age of 24 [5]. UTIs
can lead to other severe infections such as bacteraemia,
pyelonephritis and sepsis [6]. Worldwide, approximately 150
million people are diagnosed with UTI each year, which has a
great impact not only on public health, but also on the global
economy [7].
It is well documented that Escherichia coli is the main causative
agent of UTIs [8], and the extra-intestinal pathogenic E. coli
[ExPEC] group have the capability of causing community-
acquired UTIs, accounting for more than 85% of infections [9].
Over the past decade, ExPEC have shown an increased level of
antimicrobial resistance to front-line antibiotics such as trimeth-
oprim and ciprofloxacin, and resistance to these antibiotics has
been observed in as many as 20–45% of ExPEC isolates [1,10].
ExPEC have also been associated with a high level of extended
spectrum b-lactamase (ESBL) gene carriage [11,12]. This is of
great concern since it can limit the therapeutic choices used for
treating infections, and these organisms may also act as a major
reservoir of antimicrobial resistance.
Molecular epidemiological analysis of ESBL-producing ExPEC
isolates by multilocus sequence typing (MLST) has recently
uncovered the emergence of a prevalent ExPEC clone, namely,
E. coli sequence type 131 [13]. E. coli ST131 is a CTX-M ESBL
producing E. coli clone [13]. It belongs to the serotype O25:H4,
and to the highly virulent phylogroup B2 [14,15]. E. coli ST131
has been implicated as a major cause of dissemination of the
CTX-M-15 class of ESBL gene [13]. Although E. coli ST131 has
been associated with high levels of antimicrobial resistance, it has
been suggested to display increased pathogenesis [16], countering
the hypothesis that high levels of antimicrobial resistance come at
the expense of a fitness advantage, which leads to decreased
pathogenesis [1]. Several studies have reported an increased
virulence associated gene (VAG) carriage in ST131 isolates [17],
and have also found them responsible for causing a range of
severity in disease cases [18,19].
Previous work conducted in our laboratory reported the
presence of E. coli showing high levels of antimicrobial resistance
in a collection of monomicrobial and polymicrobial urine samples
[10]. Further characterisation of the isolates found that ST131 was
the predominant strain type within the collection, that the ST131
strains were responsible for the high levels of antimicrobial
resistance in the collection and that there were variations in VAG
profile between strains with no specific VAG profile associated
with ST131 [20]. Although the possession of specific virulence
factors, such as adhesins and iron acquisition determinants [21],
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enhances the ability of E. coli to cause a UTI, ST131 has not
shown a significant difference in its VAG carriage compared to
other uropathogenic E. coli (UPEC) of different STs such as E. coli
ST73, ST69 and ST127 [20,22]. This questions the role of VAG
carriage in the current success of ST131 [15,23], suggesting the
presence of other factors that can contribute to ST131 fitness.
Several reports have proposed that bacterial metabolic potential
can enhance fitness leading to increased pathogenesis. For
example, previous studies have shown that sugar metabolism in
enterobacteria [24], and the possession of specific metabolic
enzymes [25], may increase bacterial virulence. A recent study
comprising 47 biochemical tests using the Vitek2 Advanced Expert
System for metabolic profiling on a collection of 300 UPEC
isolates concluded that ST131 isolates have higher metabolic
potential profiles in comparison to other ST isolates. It also
showed that ST131 isolates have a significant association with
eight biochemical tests including those for peptidase, decarboxyl-
ase, and alkalinisation activity. Moreover, it also found a
correlation between metabolic activity and antibiotic susceptibility
profiles, with multi-drug resistant isolates showing the highest
metabolic potential [26].
In this study, we tested and compared the metabolic activity of a
collection of extra-intestinal pathogenic E. coli isolates including
ST131 and non-ST131 isolates, using all available API metabolic
profiling substrates (Biomerieux, UK). We further tested the
metabolic activity of ten E. coli isolates to a more comprehensive
level using Biolog automated phenotypic microarray technology in
order to provide a comparison between ST131 and E. coli of
different STs in terms of their global metabolic potential, and to
examine the correlation between the antimicrobial resistance and
the metabolic activity of ST131 isolates. Our data agrees with that
of Gibreel et al (26) in that analysis of a limited number of
metabolites can produce differential profiles for different sequence
types. However, our Biolog analysis demonstrated no detectable
difference in metabolic fitness between ST131 and other ExPEC
sequence types, suggesting E. coli ST131 does not display elevated
metabolic fitness. In addition we reanalysed the genome sequences
of a dozen ST131 isolates previously sequenced by our group
[27,28] creating an ST131 core genome which we compared
against reference ExPEC genome sequences, showing that there is
little difference at the genome level in presence or absence of
metabolic operons.
Materials and Methods
Bacterial Strains
A collection of fifty E. coli isolates, twenty five ST131 and twenty
five non-ST131 isolates, were included in the metabolic profiling
assay. Thirty six of these isolates were collected between October
2008 and June 2009 from urine samples of elderly patients from
Queens Medical Centre, Nottingham, while the other fourteen
isolates were collected between March 2011 and June 2011 from
urine samples of patients from Queens Medical Centre, Notting-
ham. The MLST of the isolates and identification of virulence
factors and antibiotic susceptibility profiles have been previously
described [10,20,29]. A subset of ten E. coli isolates, five ST131
and five E. coli non-ST131, were used to carry out the Biolog
phenotypic microarray assay. The five ST131 isolates were
previously genome sequenced [27], and varied in CTX-M-15
gene carriage, source of isolation, and invasion levels. The non-
ST131 isolates were chosen to represent the major ExPEC STs
associated with human disease [20]. Table 1 shows full details of
the strains used in the phenotypic microarray assay.
Metabolic Profiling Assay by API Reagents
Four API kits: API 20E, ID32 E, API 50 CH and API ZYM kits
(Biomerieux, UK) were used in metabolic profiling. This resulted
in a total of 120 biochemical tests and allowed the measurement of
carbon source utilisation, carbohydrate fermentation and enzy-
matic activity of E. coli isolates. Preparation of bacterial
suspensions and inoculation of test kits were performed according
to the manufacturer’s instructions (Biomerieux, UK). The assays
were performed in duplicate on two independent occasions giving
completely concordant results.
Biolog Phenotypic Microarray (PM) Assay
The PM assay was performed using Biolog Inc. (Hayward, CA).
This assay consisted of two 96 well PM panels (PM1, PM2A),
which were used to test the ability of five E. coli ST131 and five
non-ST131 isolates to utilise 190 carbon sources. E. coli isolates
were plated out on LB agar (Fisher Scientific, UK) at 37uC prior to
starting the assay. The bacterial cell suspension for each isolate
was prepared by transferring around 20–25 bacterial colonies into
a sterile tube containing 15 ml of sterile dH2O. A uniform
suspension was made until a turbidity of 42% transmittance (T)
61% in the Biolog turbidimeter was obtained. Two millilitres of
this cell suspension was then added to 10 ml of inoculation fluid-0
(IF-0)+120 ml dye A to yield a final cell density of 85% T.
Afterwards, 100 ml of the 85% T cell suspension was added to
each well. The plates were then placed in the OmniLog reader
(Biolog), and incubated for 48 h. The OmniLog reader analyses
the plates every 15 minutes, converting the pixel density in each
well to a signal value reflecting cell growth and dye conversion.
Phenotypic microarray data analysis was performed using a signal
value calculation approach described previously by Homann et al
[30]. Each substrate was tested in duplicate per strain.
Statistical Analysis
The production of heat maps for API metabolic profiling results
was performed using SPSS PAWS (version 20.0) statistics software.
Phenotypic microarray results were analysed using R statistics
package. The significance of association between E. coli STs and
different biochemical tests used for the metabolic profiling assay
was determined by performing Fisher’s exact test (FET) in a
pairwise fashion, and the threshold for statistical significance was a
P value of #0.05. Testing for correlation between metabolic
profile and sequence type was performed by principal component
analysis (PCA) in R.
Comparative Genomics
To compare metabolic potential between strains at a genomic
level, an ST131 core genome was created to ensure any differences
observed were conserved across all the ST131 strains. This was
done as previously described by our group [28] using all available
ST131 genomes [27]. The ST131 core genome was then
compared against CFT073, UTI89, and P5B (table 1) using
ACT [31] in a pairwise fashion to determine metabolic loci
uniquely present or uniquely absent to ST131.
Results
API Test Results Identify a Small Number of ST131
Discriminatory Tests
120 API test reagents were used to perform metabolic profiling
on twenty five ST131 and twenty five non-ST131 isolates
belonging to the four major ExPEC sequence types: ST69,
ST73, ST95 and ST10. Figure 1 shows a comparison of results
ST131 Biolog comparison
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obtained from selected biochemical tests for all fifty E. coli ST131
and non-ST131 isolates. All isolates were positive for utilisation of
thirty substrates, and negative for forty three others, with
variations between STs in terms of their capability of utilising
the remaining forty seven substrates.
ST131 isolates exhibited a strong trend in the inability to utilise
five tested substrates: 5-keto-D-gluconate (5KG), D-ARAbinose
(DARA), esculin, cellobiose and dulcitol, in comparison to other
ST isolates. With regard to 5KG utilisation, only 2 of the 25
ST131 isolates (8%) were able to utilise this substrate, whilst the
utilisation percentages for ST69, ST73, S795 and ST10 isolates
were 100%, 85%, 66% and 60%, respectively. Additionally,
ST131 isolates exhibited poor DARA utilisation compared to
other ST isolates. Only 20% of ST131 isolates were able to utilise
this substrate compared to 100% for ST69 isolates, 85% for ST73
isolates, 100% for ST95 isolates, and 60% for ST10 isolates.
Similarly dulcitol utilisation percentage for ST131 isolates was
36% compared to 100% for ST69 isolates, 85% for ST73 isolates,
83% for ST95 isolates, and 60% for ST10 isolates. The capability
of ST131 isolates to utilise esculin was 24% compared to 42% for
ST69, 100% for ST73, 66% for ST95 and 100% for ST10
isolates. The cellobiose utilisation percentage for ST131 isolates
was 12% compared to 42% for ST69 isolates, 50% for ST73
isolates, 33% for ST95 isolates, and 40% for ST10 isolates.
ST131 isolates did not show higher metabolic activity for any
biochemical substrate tested when compared to other ST isolates,
which is in contrast to the previous study [26]. The ability of
ST131 to utilise substrates for which it was more active in that
study, such as ODC, bGUR and SAC, was not higher using API
methodology, while some other substrates do not appear in the
API substrate panel.
Table 1. Details of strains used in the phenotypic microarray assay.
Strain E. coli ST Strain history Patient source CTX-M carriage Reference
UTI18 ST131 UTI Community CTX-M-15 [20]
UTI32 ST131 UTI Hospital CTX-M-15 [20]
UTI226 ST131 UTI Hospital – [20]
UTI570 ST131 UTI Community – [20]
UTI587 ST131 UTI Community CTX-M-15 [20]
UTI396 ST393 UTI – – [20]
UTI501 ST69 UTI – – [20]
UTI89 ST95 Uncomplicated cystitis – – [39]
CFT073 ST73 Acute pyelonephritis – – [40]
P5B ST10 Bacteraemia – – [41]
doi:10.1371/journal.pone.0088374.t001
Figure 1. Heat map showing a comparison of results obtained from testing 25 API biochemical substrates on E. coli ST131 and four
major ExPEC STs representing the whole substrates used in phenotypic profiling assay. Darker shaded areas indicate higher percentage
of strains capable of utilizing the substrate. The inability of ST131 to utilise 5KG, Dulcitol (DUL), DARA, cellobiose and esculin is highlighted by red
circle.
doi:10.1371/journal.pone.0088374.g001
ST131 Biolog comparison
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Biolog Phenotypic Microarray Assay Shows No Significant
Difference in Metabolic Capacity between ST131 and
Other ST Isolates
In light of the contrasting results above with a previous study
showing ST131 enhanced metabolic function, we utilised the
superior discriminatory power of the phenotypic microarray assay
to fully characterise the metabolic capacity of five E. coli ST131
and five non-131 isolates. Figure 2 shows a heat map for all
metabolites tested, with values corresponding to the intensity of
utilisation for the different nutrient sources. There were very few
detectable differences in the metabolic capacity between ST131
and other ST isolates for the majority of tested carbon sources. As
with the commercial test reagents there were some strain-specific
differences in metabolite utilisation but these were not consistent in
either ST131 or non-ST131 groups, and ST131 isolates were not
associated with a specific metabolic profile.
Considering the metabolic activity of CTX-M-15 producing
ST131 isolates, UTI32 showed higher metabolic potential in
comparison to other ST131 isolates as its signal values were the
highest for a range of substrates such as M-inositol, palatinose, D-
tagatose, malonic acid and N-acetyl-L-glutamic acid, L-histidine
and L-phenylalanine and putrescine. In contrast it also showed the
lowest utilisation levels for other substrates including N-acetyl-D-
galactosamine, and signal values for D-raffinose and L-malic acid
were lower than for other ST131 and non-ST131 isolates. UTI587
showed a lower potential for utilising the following substrates:
dulcitol, glycyl-L-glutamic acid, 3-0-b-d-galacto-pyranosyl and
melibionic acid. Additionally, UTI18 had the lowest signal value
for a-Keto-butyric acid substrate among ST131 isolates. The
Figure 2. Cluster heat map showing the signal values of E. coli ST131 and non-ST131 isolates obtained from 190 biochemical tests
using PM assay, with red showing no utilisation through to green showing high levels of utilisation. A UPGMA dendrogram informed by
the metabolic profile is presented above the heatmap. ST131 strains are represented by red blocks, and non-ST131 strains by blue blocks.
doi:10.1371/journal.pone.0088374.g002
ST131 Biolog comparison
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ST131 CTX-M-15 negative isolate, UTI226, had the highest
metabolic activity among ST131 isolates for pyroglutamic acid,
chondroitin sulfate c, b-cyclodextin, amygadin, gentiobiose and D-
lyxose carbon sources. In contrast it also had the lowest ability to
utilise b-hydroxy-butyric acid compared to other ST131 isolates.
Taken together our data suggests that ESBL gene carriage is not
associated with a specific metabolic activity profile within the
ST131 isolates, and that variation is on a more generic strain to
strain level. With respect to the metabolic activity of non-ST131
isolates, UTI89 exhibited an increased ability to metabolise some
carbon sources compared to other isolates, and was the only isolate
capable of utilising carbon sources such as tyramine, gelatin,
xylitol, G-amino-butyric acid and D,L-octopamine. Additionally,
the signal values of UTI89 were higher than that of other isolates
for D-arabitol, L-arabitol and 3-methyl glucose.
In short, although there are some differences in the metabolic
traits between isolates, these differences are very much strain-
specific and are not detected at a sequence type level. The
generation of a UPGMA dendrogram based on utilisation of
metabolites confirmed this, with the ST131 and non-ST131 strains
equally dispersed throughout the dendrogram, suggesting that
ST131 are not a metabolically distinct group of ExPEC strains.
Principal Component Analysis of Phenotypic Microarray
Data Set Confirms the Non-existence of an ST131
Metabolic Cluster
To further confirm that ST131 are not a metabolically distinct
group of ExPEC strains, we performed principal component
analysis on the phenotypic microarray metabolic profile data set.
The PCA1/PCA2 plot (Figure 3) shows clearly that ST131 isolates
are not grouped based on metabolic properties, but rather are
dispersed throughout the PCA plot amongst the non-ST131
isolates. In conjunction with the heat-map based dendrogram our
data suggests that E. coli ST131 are not a metabolically distinct
clade of ExPEC.
Comparative Genomic Analysis Confirms the Absence of
ST131 Associated Metabolic Loci
Given that the vast majority of the strains analysed by
phenotypic microarray in our study have been genome sequenced
[27,28] we sought to further confirm our metabolism observations
by correlating them to gene presence/absence data at a whole
genome level. We adapted an approach recently used to
successfully identify clade specific metabolic functions in Campylo-
bacter [32] by constructing an ST131 core genome and then
comparing this against the CFT073, UTI89, and P5B genomes
(table 1) using ACT [31], concentrating on genes and operons with
predicted or confirmed metabolic functions.
Our data showed that the vast majority of core ST131 specific
genes, and indeed genes not present in all ST131 were phage,
transposon, and IS associated sequences. With respect to
metabolism we found only 3 clear differences in the idn, ydd, and
asc operons, which we have previously reported [27]. These three
operons are involved in utilisation of two of the five metabolites
(5KG and cellobiose) identified as being under-utilised in ST131
strains by API. The idn operon is a subsidiary pathway for the
gntII gluconate metabolism system, and the ydd A and B genes are
transporters for the gntI gluconate system, whilst the asc operon
encodes a combined arbutin/salicin/cellobiose uptake and
metabolism pathway. Figure 4 shows ACT comparisons of the
three loci from CFT073 and the core ST131 genome. Gene
content differences relating to the other three differential
metabolites could not be found. Therefore our data suggests that
presence or absence of loci does not correlate well with metabolic
profile. This indicates that the subtle differences that have been
observed in metabolism of substrates in ST131 compared to other
ExPEC may not be clearly distinguishable at a genome level and
may be down to discreet mutations in other upstream or
downstream metabolic pathways which then impinge on metab-
olism of the identified differential substrate.
Discussion
Metabolism is an important factor in bacterial colonisation of
any given environment, and in particular of animal and human
hosts. It is suggested that bacteria may need an extensive
metabolic repertoire to accommodate changes in pH and nutrient
availability that result from their transition from the environment
to a within-host niche [33]. Several studies have demonstrated the
role of metabolism in enhancing the colonisation and virulence of
E. coli. For example, the increased capability of the E. coli CFT073
strain to catabolise the amino acid D-serine during UTI can lead
to increased levels of colonisation and virulence gene expression
[34]. Similarly a recent study has shown that enterohaemorrhagic
E. coli (EHEC) uses fucose to modulate its virulence and metabolic
genes [35].
A recent study focussed on the metabolic potential of E. coli
ST131, the most commonly isolated cause of extra-intestinal E. coli
infections world-wide and a recently emerged clone of ExPEC
associated with multi-drug resistance [26]. The study examined
the ability of ST131 drug resistant and sensitive isolates to utilise
47 biochemical substrates in comparison to non-ST131 ExPEC
strains, using the Vitek2 Advanced Expert System for metabolic
profiling. In total 300 UPEC isolates were compared, with the
study concluding that ST131 isolates have higher metabolic
potential in comparison to other ST isolates on the basis of their
ability to utilise more of the substrates than non-ST131 isolates.
The study showed a significant association between ST131 isolates
and utilisation of eight biochemical tests including those for
peptidase, decarboxylase, and alkalinisation activity. Additionally
the study also described a correlation between metabolic activity
and antibiotic susceptibility profiles, with ESBL carrying, multi-
drug resistant isolates showing the highest metabolic potential
[26].
In the study we report here, we tested and compared the
metabolic activity of a collection of extra-intestinal pathogenic E.
coli isolates including ST131 and non-ST131 isolates, employing
another commonly used commercial metabolic profiling system
(Biomerieux, UK). Our data agrees with that of Gibreel et al in
that analysis of a limited number of metabolites can produce
differential profiles for different sequence types. Our study showed
reduced metabolic capacity of ST69 to utilise ODC, and of ST95
to utilise SAC. With respect to ST131 our data showed lower
metabolic activity for five substrates, namely 5-keto-D-gluconate
(5KG), D-ARAbinose (DARA), esculin, cellobiose and dulcitol in
comparison to other major ExPEC STs. Some of these findings
are in direct agreement with the Gibreel study which also
demonstrated a significant negative association between ST69 and
ODC, between ST95 and SAC, and between ST131 and 5KG
[26]. However the major discussion point of the Gibreel study,
that ST131 are more metabolically flexible and ‘‘fit’’ is in
disagreement with the data produced using API biochemical tests.
Of the Vitek positive association tests which also feature in the API
test panel (ODC, bGUR and SAC) none showed higher levels of
metabolism in ST131 isolates compared to non-ST131 ExPEC.
The most likely explanation for this is due to differences in the way
substrate utilisation is measured between the fully automated Vitek
ST131 Biolog comparison
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system and the API test strip method. The validity of this as a
potential explanation for the discrepancy is highlighted by
comparison of our results for dulcitol utilisation in ST131 when
measured by API and by phenotypic microarray. Our phenotypic
microarray data showed very little difference in dulcitol utilisation
between ST131 and other ST isolates, in complete contrast to the
API data. This is almost certainly due to the fact that the PM
plates are used to measure carbon source oxidation and not sugar
fermentation as in the API test [36]. Therefore we suggest that
different utilisation capabilities between strains could be observed
depending on the principle of assay used to determine the
metabolic activity.
Using a total of forty seven biochemical tests on three hundred
isolates the Gibreel study concluded ST131 strains are metabol-
ically more flexible. However our data of one hundred twenty
biochemical tests on fifty isolates is suggestive of ST131 strains
having slightly reduced metabolic potential. In an attempt to
further determine the metabolic profile of ST131 E. coli in
comparison to other ExPEC, we compared ten isolates using
Biolog phenotypic microarray technology, five ST131 and five
non-ST131 ExPEC. Phenotypic microarrays have been utilised to
study the metabolic flexibility of various bacterial species [37] and
provides the highest level of resolution currently available for the
metabolic capacity of cells. Heat map visualisation of our data
indicates there is no distinct metabolic signature for E. coli ST131
and that any differences in metabolic repertoire are at an
individual strain level rather than by sequence type grouping.
This is further supported by a principal component analysis of the
microarray data, showing there is no clustering of ST131 based on
metabolic repertoire. An obvious caveat to our findings is the
limited number of strains examined. However our comparison is
of five ST131 strains, all of which have previously been shown to
Figure 3. Principal component analysis for metabolic profiles obtained from an analysis of the phenotypic microarray data set.
ST131 strains are denoted by red blocks, and non-ST131 strains by blue blocks.
doi:10.1371/journal.pone.0088374.g003
ST131 Biolog comparison
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be genetically homogeneous and phylogenetically clustered with
the EC985 and NA114 genome sequenced strains [27,28].
Therefore if ST131 were a metabolically distinct clade of ExPEC
with enhanced metabolic potential we would expect to see some
form of clustering of our 5 isolates by principal component analysis
of the phenotypic microarray data.
Given that the genome sequences of almost all of the strains
subjected to phenotypic microarray are available we sought to
contextualise our metabolism findings at a whole genome level.
We created an ST131 core genome as previously described by our
group [28] the rationale being that any ST131-discriminating
metabolic repertoire would have an accompanying genetic
signature associated with the ST131 clade. This was then
compared to the genomes of CFT073, UTI89, and P5B. Our
data failed to uncover any substantial differences in the metabolic
gene repertoire of ST131 compared to the three other ExPEC
genomes. However, when we focussed on operons responsible for
the 5 discriminatory tests identified by API (5-keto-D-gluconate
(5KG), D-ARAbinose (DARA), esculin, cellobiose and dulcitol) we
could find genetic deletions that would account for only two of
those phenotypes, in the idn and ydd operons involved in 5KG
metabolism and the asc operon involved in cellobiose uptake. Our
data appears to suggest that differences in metabolic repertoire
between bacteria cannot simply be mapped to genome data and
gene presence or absence. It is likely that small mutations in
pathways complexly linked to the metabolic function observed
could result in knock on effects which would be extremely difficult
to pinpoint and associate with the phenotype under investigation.
In conclusion, it is our opinion that the previous study of E. coli
ST131 metabolism performed by Gibreel et al [26] excellently
identifies metabolic markers which could have enormous impor-
tance in rapid identification or selection of ST131 isolates in
human samples. In our study, we concurred that the use of a
limited number of biochemical tests can produce differential
profiles for different sequence types. Our phenotypic profiling data
supports this as we found clear differences in the metabolic activity
between ST131 and non-ST131 strains for 5 of 120 biochemical
substrates. However, when we comprehensively tested the global
metabolic repertoire of a limited number of E. coli strains using the
phenotypic microarray system, we found no difference in the
overall metabolic fitness between ST131 and non-ST131 isolates.
In addition, comparison of genomic data also suggested very little
difference in the repertoire of metabolic gene loci between ExPEC
sequence types.
The current ST131 literature seems highly confused with
respect to the reasons behind the success of the E. coli ST131
clone. Early PCR based studies attributed this to the combination
of phylogenetic group B2 and the presence of specific virulence
factors such as pathogenicity island marker (malX), outer mem-
brane protein (ompT) and uro-pathogenic specific protein (usp)
being more common among ST131 than in other CTX-M
producing E. coli strains, and suggested that these factors might
play a major role in the worldwide dissemination of ST131 [13].
Another study suggested that the rapid global spread of the CTX-
M-15 producing E. coli might be due to the acquisition of the
IncFII plasmids which are associated with harbouring many
antimicrobial resistance genes [38]. Johnson and colleagues have
Figure 4. ACT comparisons of the (A) idn (B) ydd and (C) asc loci from CFT073 (upper genome) and the core ST131 genome (lower
genome).
doi:10.1371/journal.pone.0088374.g004
ST131 Biolog comparison
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demonstrated that undefined phylogenetic group B2-associated
factors may provide a fitness advantage to ST131 [19], whilst the
recent paper on which our work was based suggested ST131
strains were more metabolically active [26].
Our previous work describing the genetic homogeneity of
ST131 [27] combined with the data presented here provide yet
another confounding hypothesis that E. coli ST131 do not display
altered metabolic fitness to other closely related ExPEC from a
global metabolic and genomic perspective. An obvious caveat to
both our findings and those of Gibreel et al is that different strain
sets have been compared using different methodologies, and
indeed this may be applicable to many of the dichotomous results
in the literature regarding ST131. We propose that a co-ordinated
international effort to fully understand the evolutionary mecha-
nisms behind the emergence of E. coli ST131 is now imperative in
order to combat this most serious of bacterial pandemics, and of
future episodes of novel E. coli lineage emergence.
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